Sol-Gel Technologies Ltd. (SLGL)
Nasdaq · Healthcare · Biotechnology
$78.95+9.65%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $259M
- 52-week range
- $28.81 – $97.97
- 52-week change
- +75.65%
- EPS (trailing)
- −$5.61
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 19, 2026
Fiscal year to Dec 2025
- Revenue
- $19.4M (+68.04%)
- Net income
- −$6.1M
- Operating margin
- −38.9%
- Diluted EPS
- −$2.19
- Free cash flow
- $280K
From the company’s annual report on SEC EDGAR.
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Headquarters: Ness Ziona, Israel · 28 employees · sol-gel.com